Autologous t-cells expressing a chimeric antigen receptor directed to b-cell maturation antigen (bcma) in patients with generalized myasthenia gravis (MG)
Ended Project Grant Awarded Last action
- Award ID
- R44NS115426
- Recipient
-
Cartesian Therapeutics Inc. UEI PXGLS86SY6B1
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,298,932
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Funding
-
- $3,144,574.00 Federal
- $1,154,358.00 Non-federal
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,154,358 | $0 | |
| Amendment | $1,154,358 | $1,154,358 | |
| Original award | $835,858 | $0 |
Quick answers
Who received award R44NS115426?
R44NS115426 was awarded to Cartesian Therapeutics Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on April 15, 2020.
How much is award R44NS115426 worth?
$4,298,932 has been obligated on R44NS115426: $3,144,574 in federal funding and $1,154,358 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award